AndroGel Geriatric (65+) Dosing: What Clinicians and Patients Should Know

Why Geriatric Dosing Differs from Standard Adult Dosing

Older men metabolize testosterone differently than younger adults, and this difference shapes every prescribing decision. Age-related declines in renal clearance, hepatic blood flow, and lean body mass alter drug distribution. The FDA-approved labeling for AndroGel does not specify a separate geriatric dose, but clinical practice strongly favors a "start low, go slow" approach.

The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that daily application of 1% testosterone gel restored testosterone into the mid-normal range within 12 months 1. Participants used a dose-titration protocol targeting 500 ng/dL at trough. This trial population had a mean age of 72, making it the most direct evidence base for geriatric testosterone gel prescribing.

Renal impairment affects roughly 38% of adults over 65, according to CDC prevalence data 2. Reduced glomerular filtration rate does not change testosterone gel absorption (which is transdermal), but it does affect the clearance of testosterone metabolites and concurrent medications. A 74-year-old on five prescription drugs is not the same patient as a 45-year-old on none. The dosing framework reflects that reality.

The Endocrine Society's 2018 clinical practice guideline recommends that clinicians "inform patients of the absence of evidence of benefit" of testosterone therapy in men who have age-related decline but whose testosterone is not clearly low, and advises against prescribing testosterone to men over 65 solely to prevent frailty 3.

Starting Dose: 1% vs. 1.62% Formulations

The right starting dose depends on which AndroGel concentration the patient receives. These are not interchangeable products. For the 1.62% gel, the starting dose is one pump actuation delivering 20.25 mg of testosterone. For the 1% gel, the starting dose is one 50 mg packet or equivalent pump actuations.

Both formulations are applied once daily to the shoulders, upper arms, or abdomen (never to the scrotum or chest). Absorption varies by site and by individual skin thickness, which tends to be thinner in older adults. The Endocrine Society guideline notes that transdermal formulations are preferred in older men because they avoid the supraphysiologic peaks seen with intramuscular injections, peaks that carry higher cardiovascular and erythrocytosis risk 3.

A common clinical error is starting a geriatric patient at mid-range or high doses. The package insert for AndroGel 1.62% lists a dose range of 20.25 mg to 81 mg per day, but the FDA labeling explicitly states that dose adjustment should be based on serum testosterone measured approximately 14 days after starting therapy or after any dose change 4. Starting at 20.25 mg and titrating upward by 20.25 mg every two to four weeks until trough testosterone reaches 300 to 600 ng/dL is the safest path for a 65+ patient.

Titration Protocol for Older Men

Titration should be methodical. Draw a morning serum total testosterone (before that day's gel application) at 14 days. If the level is below 300 ng/dL, increase by one pump actuation (20.25 mg for 1.62%; 25 mg for 1%). Recheck at 14 days after each adjustment.

If testosterone exceeds 600 ng/dL on the starting dose, reduce or discontinue. The AUA/Endocrine Society consensus states that target trough levels for transdermal therapy should remain in the lower half of the reference range, particularly for older men 3. The reasoning is straightforward: supraphysiologic testosterone in a 70-year-old correlates with higher hematocrit, elevated PSA velocity, and increased cardiovascular event rates.

Some geriatric patients absorb topical testosterone poorly due to skin atrophy, reduced subcutaneous fat, or concomitant use of emollients. If two dose increases fail to bring trough testosterone above 300 ng/dL, consider switching to a different delivery method rather than escalating to maximum gel doses. The T-Trials found that roughly 12% of participants required dose adjustments to maintain target levels, illustrating the variability in transdermal absorption 1.

Lab Monitoring Schedule

Geriatric patients require more frequent lab work than younger men on testosterone replacement. The minimum monitoring panel includes total testosterone, hematocrit, PSA, and a lipid panel.

Baseline (before starting therapy): total testosterone (two morning draws on separate days), free testosterone, hematocrit, PSA, comprehensive metabolic panel, lipid panel, and a digital rectal exam or urology referral if PSA is above 4.0 ng/mL.

Week 2 to 4: serum total testosterone trough to guide dose titration.

Month 3: testosterone, hematocrit, and PSA. The Endocrine Society recommends holding testosterone therapy if hematocrit exceeds 54%, as erythrocytosis increases thromboembolic risk 3. Dr. Shalender Bhasin, the principal investigator of the T-Trials, has stated that "hematocrit monitoring is not optional in older men on testosterone; it is the single most actionable safety lab" 5.

Month 6 and 12: full panel including testosterone, hematocrit, PSA, lipids, and metabolic panel.

Annually thereafter: same full panel, with bone density (DXA) every one to two years if osteoporosis was part of the treatment indication.

A PSA velocity exceeding 1.4 ng/mL per year warrants urology referral regardless of absolute PSA value. This threshold comes from the AUA's position statement on testosterone therapy and prostate cancer monitoring 6.

Cardiovascular Risk in Men Over 65

Cardiovascular safety is the dominant concern in geriatric testosterone prescribing. The TRAVERSE trial (N=5,204, mean age 63) found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months 7. The hazard ratio for the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) was 0.99 (95% CI 0.81 to 1.21).

This result shifted clinical consensus. Before TRAVERSE, the 2015 FDA label warning about cardiovascular risk led many clinicians to avoid prescribing testosterone to men over 65 entirely. The 2023 data from TRAVERSE provides reassurance, though the Endocrine Society notes that men with NYHA class III or IV heart failure, recent MI (within 6 months), or recent stroke remain poor candidates 3.

Blood pressure monitoring matters. Testosterone can cause fluid retention, and geriatric patients often take ACE inhibitors, ARBs, or diuretics. A study published in JAMA Internal Medicine found that testosterone therapy was associated with a 3 to 5 mmHg increase in systolic blood pressure in older men 8. For a patient already at 145/90, that increment is clinically meaningful.

Drug Interactions and Polypharmacy

Men over 65 take a median of five prescription medications, according to CDC data on polypharmacy prevalence 9. Several common drug classes interact with testosterone.

Warfarin and direct oral anticoagulants: Testosterone increases the anticoagulant effect of warfarin. The mechanism involves altered synthesis of clotting factors. If the patient takes warfarin, INR should be checked within one week of starting AndroGel and rechecked after each dose adjustment 4. Direct oral anticoagulants (rivaroxaban, apixaban) have less interaction potential, but vigilance is still warranted.

Insulin and oral hypoglycemics: Testosterone may improve insulin sensitivity. The T-Trials showed a modest reduction in HbA1c (mean decrease 0.03%) in treated men with type 2 diabetes 10. Hypoglycemia risk increases if insulin doses are not adjusted downward.

Corticosteroids: Concurrent use of systemic corticosteroids can exacerbate fluid retention and edema, a combination that is poorly tolerated in older men with borderline cardiac function.

5-alpha reductase inhibitors (finasteride, dutasteride): These drugs reduce conversion of testosterone to dihydrotestosterone (DHT). They do not contraindicate testosterone therapy, but they may blunt certain androgenic effects (body hair, prostate growth). PSA interpretation becomes more complex because 5-alpha reductase inhibitors lower PSA by roughly 50%.

A comprehensive medication reconciliation before initiating AndroGel in any patient over 65 is not a suggestion. It is a clinical requirement.

Falls, Fractures, and Physical Function

The T-Trials Physical Function Trial enrolled 209 men with mobility limitations and found that testosterone gel improved self-reported walking ability but did not significantly improve 6-minute walk distance compared to placebo 11. The effect was modest: a mean increase of 6.1 meters in the testosterone group versus placebo.

Bone density data from the T-Trials Bone Trial showed that testosterone increased volumetric bone mineral density of the spine by 7.5% and estimated bone strength by 10.8% over 12 months compared to placebo, as measured by quantitative CT 12. These are meaningful changes in a population where vertebral compression fractures carry significant morbidity.

Falls are the leading cause of injury death in adults over 65, according to the CDC 13. Testosterone therapy may reduce fall risk indirectly by improving muscle mass and bone density, but evidence for a direct fall-prevention effect is lacking. Do not prescribe AndroGel as a falls-prevention strategy. Prescribe it for documented hypogonadism and track fall-related outcomes as a secondary measure.

When to Deprescribe Testosterone in Older Men

Not every 65-year-old who starts testosterone should stay on it indefinitely. Deprescribing should be considered when the original indication no longer applies, when risks begin to outweigh benefits, or when the patient's goals of care shift toward comfort rather than optimization.

Specific triggers for deprescribing include: hematocrit persistently above 50% despite dose reduction, new diagnosis of hormone-sensitive prostate cancer, PSA velocity exceeding 1.4 ng/mL per year, severe untreated sleep apnea, or patient preference.

Abrupt discontinuation is usually well-tolerated with transdermal testosterone because serum levels decline gradually over 24 to 48 hours. Unlike injectable testosterone, which can produce withdrawal-like symptoms due to rapid hormonal fluctuation, gel cessation is physiologically gentler. Dr. Alvin Matsumoto from the University of Washington, a co-investigator on the T-Trials, has noted that "the transdermal route offers the most graceful exit ramp when therapy is no longer appropriate" 14.

Monitor testosterone and symptom burden at 4 and 12 weeks after discontinuation. If symptoms of hypogonadism recur and labs confirm low testosterone, the decision to restart should incorporate updated cardiovascular and prostate risk assessment.

Application Tips Specific to Older Patients

Skin in older adults is thinner, drier, and more fragile. Apply AndroGel to intact, clean skin only. Avoid areas with cuts, abrasions, or dermatitis. Do not apply to skin that has been recently treated with topical corticosteroids, as this can alter absorption.

Transference risk is a labeled black box warning. Older men who live with grandchildren or partners should apply the gel to areas that remain covered by clothing, wash hands immediately after application, and cover the application site with a shirt. The FDA label specifies that skin-to-skin contact can transfer enough testosterone to cause virilization in children or women 4.

For men with arthritis or limited hand dexterity, the pump formulation (1.62%) may be easier to use than individual packets. Each pump actuation delivers a consistent 20.25 mg dose, reducing the risk of spills or uneven application that can occur when tearing open foil packets.

Apply at the same time every morning. Showering, swimming, or heavy sweating within two hours of application reduces absorption. If the patient applies sunscreen or lotion to the same area, allow the gel to dry completely (at least five minutes) before layering other topical products.

Red Flags That Require Immediate Dose Hold or Referral

Stop AndroGel and contact the prescribing clinician if: hematocrit exceeds 54% on any lab draw, PSA rises by more than 1.4 ng/mL within 12 months, the patient develops new lower urinary tract symptoms (LUTS) with IPSS score increase of 5 or more points, the patient experiences chest pain or new-onset shortness of breath, or signs of secondary polycythemia appear (facial plethora, headache, blurred vision). These are not dose-adjustment situations. They are stop-and-evaluate situations.